| Accession |
PRJCA014975 |
| Title |
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of HLX22 in Patients with Advanced Solid Tumours Overexpressing HER2 |
| Relevance |
Medical |
| Data types |
Metabolite data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the safety and maximum to leated dose (MTD) of HLX 22 in patients with advanced or metastatic solid tumours which are non-responsive to standard therapies,screening 20 patients, enrolment 11 Patients. |
| Sample scope |
Multiisolate |
| Release date |
2023-02-15 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Yanhua
Ding (18343115092@163.com)
|
| Organization |
The First Hospital of Jilin University |
| Submission date |
2023-02-15 |
